No abstract

The surfactant market represents a key sector of the chemical industry and encompasses many diverse applications. Their sustainability in terms of feedstock used, synthetic procedure, biodegradability, and formulation are crucial parameters to assessing the environmental impact of the surfactant. The anionic surfactant linear alkyl benzene sulfonates have proven successful to date because of their high performance, low cost, and extensive studies within formulations to optimize performance, allowing usage in a large variety of applications, especially in cleaning. Due to their advantageous properties and extensive research and development, their substitution with a biobased surfactant such as sodium dodecyl sulfate has struggled to succeed. Furan surfactants have been reported as valuable candidates for the implementation of green alternatives to traditional anionic sulfonated surfactants with a perfect trade-off between performances and green credentials. However, their implementation suffers of scalability and high cost in producing the final product due to feedstock availability and low yields of the final product. Herein, we report a new class of furan surfactants, sulfonated alkyl furoates, which are derived from the esterification of furoic acid and fatty alcohols, followed by a sulfonation step. Compared to traditional surfactants, they showed more favorable behavior in basic proprieties (such as critical micelle concentration, ecotoxicity, hard water resistance, surface tension water/oil), which gives a good prospective for the introduction of a new biobased chemical with superior performances.

No abstract

Metabolic syndrome (MS) affects up to 40% of the population and is associated with heart failure, stroke and diabetes. Phytosterols (PS) could help to manage one or more MS criteria. The purpose of this study was to evaluate the therapeutic effect of daily supplementation of an aqueous dispersion of 2 g of free-phytosterols nanoparticles in individuals with MS over six months of intervention, compared with placebo. This double-blind study included 202 participants with MS randomly assigned into phytosterol (n = 102) and placebo (n = 100) groups. Participants were assessed at baseline, 4, 12 and 24 weeks. General health questions, anthropometric measurements and blood parameters were analysed. At week 24, the proportion of participants with high triglycerides (≥150 mg/dL) in the phytosterol group was 15.65% lower than in the placebo group (p-value = 0.023). Similarly, half of the participants in the phytosterol group decreased their waist circumference up to 4 cm compared with 0 cm in the placebo group (p-value = 0.0001). We reported no adverse effects (diarrhoea or vitamin D reduction); nonetheless, almost 70% of participants in the phytosterol group self-reported an improvement in bowel habits. Daily intake of free-PS nanoparticles improved some MS criteria; therefore, it might be a promising adjuvant therapy for individuals with MS (NCT02969720).